Physician profile
James A Barnes
NPI 1235177007
$4,703.69
in general payments reported to CMS, 2019-2025
51 companies · $786 in 2025
The $786 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,384 · 2020: $292 · 2021: $186 · 2022: $285 · 2023: $832 · 2024: $939 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,557.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $926.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $422.94 | 2019-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $412.94 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $374.19 | 2019-2025 | |
| Glaxosmithkline, LLC. | $273.15 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $258.19 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $181.81 | 2022-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $152.30 | 2019-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $125.71 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $115.95 | 2019-2025 | Capvaxive, Vaxneuvance, Vaxelis |
| Amgen INC. | $96.98 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Corcept Therapeutics | $87.29 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $84.98 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.92 | 2019-2025 | Relistor, Cycloset |
| Sanofi-Aventis U.S. LLC | $80.52 | 2019-2024 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.